Editas Medicine Inc's Customers Performance

Name: Editas Medicine Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

EDIT

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


EDIT's Source of Revenues		During the corresponding time, Editas Medicine Inc recorded a revenue increase by 232.31 % year on year, sequentially revenue grew by 319.99 %. While revenue at the Editas Medicine Inc 's corporate clients • List of EDIT Customers

for the same period Editas Medicine Inc recorded revenue increase by 232.31 % year on year, sequentially revenue grew by 319.99 %.

• List of EDIT Customers

Editas Medicine Inc's Business Units


Reportable		123.81 %	of total Revenue

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Editas Medicine Inc's Comment on Sales, Marketing and Customers

News about Editas Medicine Inc Contracts

Advancements in Gene Editing for Sickle Cell Disease and Beta Thalassemia Editas Medicine Reports Promising Results f...

Editas Medicine, a pioneering company in the field of gene editing, presented significant advancements in their proprietary targeted lipid nanoparticle (LNP) delivery system at the European Hematology Association (EHA) 2025 Congress held in June. The focus of their findings was on the in vivo editing of the HBG1/2 promoter, a critical target for treating sickle cell disease and beta thalassemia.The study reports an impressive 58% mean editing efficiency observed five months following a single dose of the therapeutic candidate in non-human primates. This level of editing indicates a potential pathway to achieve clinically relevant outcomes for patients suffering from these hereditary blood disorders. The use...

Editas Medicine Presents Exciting Results for EDIT-301 and Achieves Astounding Revenue Growth

:
Editas Medicine, a renowned biotechnology company focused on developing transformative genome editing treatments, has recently shared groundbreaking safety and efficacy data for their innovative therapy, EDIT-301. These encouraging results were presented at the American Society of Hematology (ASH) Annual Meeting, as well as in a company-sponsored webinar. Moreover, the company has also achieved remarkable revenue growth, highlighting its commitment to advancing medical innovation.

The new data unveiled by Editas Medicine at the ASH Annual Meeting has showcased the substantial potential of EDIT-301, providing hope to patients affected by a range of blood disorders. The study, which involve...

EDIT's Stock Performance relative to it's Customers

EDIT's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Editas Medicine Inc	314.34	38.69	-108.95	87
SUBTOTAL	0.00	0.00	0.00	-

Sources: Editas Medicine Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Editas Medicine Inc’s corporate clients.
For your research, we’ve provided 9 tables on Editas Medicine Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.